Browse the evidence

The study could not establish statistical significance regarding the likelihood of delayed gastric emptying in patients on GLP-1R agonists.

Further research is needed to clarify the relationship between GLP-1R agonists and gastric emptying.

Lifestyle interventions and older antiobesity pharmacotherapies have been associated with less than 12% body weight reduction and no clear benefit to reduce MACE risk.

Practitioners should be aware that traditional weight loss methods may not significantly reduce cardiovascular risks.

Genetic predisposition to higher BMI does not predict weight regain after weight loss.

Genetic factors related to BMI may not be useful for predicting weight regain, focusing instead on abdominal obesity genetics.

Genetic effects on abdominal obesity may be more pronounced than those on general obesity during weight regain.

Understanding the differential impact of genetics on abdominal versus general obesity can inform targeted interventions.

The most common components of metabolic syndrome in the cohort were abdominal obesity and elevated blood pressure.

Understanding common MetS components can guide targeted interventions.

Low energy availability did not enhance performance when expressed relative to body mass.

Performance assessments should consider body mass to accurately evaluate the effects of energy availability.

No evidence of a relationship was found between RIR accuracy and biological sex, years of RT experience, or relative bench press strength.

RIR accuracy can be considered independent of these demographic and experiential factors.

GLP-1 receptor agonists were originally developed as glucose lowering agents.

Understanding the original purpose of GLP-1 receptor agonists can inform their use in weight management.

Semaglutide may improve wait-list times for renal transplantation by overcoming obesity as a barrier.

Addressing obesity in patients may facilitate their eligibility for renal transplantation.

Gender, household size, and education were associated with GLP-1 use and interest.

Marketers should consider demographic factors when targeting potential GLP-1 consumers.

The use of medications for obesity will likely require lifelong treatment.

Practitioners should prepare for long-term management strategies when prescribing obesity medications.

Persistence in the OMM-eligible cohort was 73.8%.

High persistence rates suggest good adherence to tirzepatide among eligible patients.

Real-world evidence suggests slower tirzepatide dose escalation than in clinical trials.

Practitioners may need to adjust expectations regarding dose escalation in real-world settings.

Obesity is projected to affect approximately half the US population by the year 2035.

Practitioners should be aware of the increasing prevalence of obesity for public health planning.

Human body weight is physiologically regulated and maintained within a relatively narrow range in most mammals, including humans.

Understanding body weight regulation can inform strategies for managing obesity.

Difficulties in achieving body weight loss and maintenance in obese subjects are partly due to physiological regulatory systems that resist weight loss.

Recognizing these physiological challenges can guide effective weight loss strategies.

Obesity is a global epidemic and a significant public health challenge.

Recognize obesity as a critical issue in public health.

Current anti-obesity medications (AOMs) include gastrointestinal lipase inhibitors, nutrient-stimulated hormone-based therapies, and emerging multi-receptor agonists.

Consider these AOMs in obesity treatment strategies.

The prevalence of obesity among youth with type 1 diabetes increased from 18.1% to 26.0% from 2008-2011 to 2020-2023.

Healthcare providers should be aware of the rising obesity rates in youth with T1D for better management strategies.

The prevalence of obesity among adults with type 1 diabetes rose from 30.5% to 38.1% from 2008-2011 to 2020-2023.

Healthcare providers should recognize the increasing obesity rates in adults with T1D for effective treatment planning.

Advancements in laparoscopic surgical technique have improved the safety and efficacy of bariatric metabolic surgery.

Surgeons should adopt new laparoscopic techniques to enhance patient outcomes in bariatric surgery.

Recent insights into pathophysiological mechanisms suggest that OSA may be divided into distinct subgroups.

Understanding the subgroups in OSA may lead to more targeted treatments.

Recent drug candidates show a convincing reduction of sleep disordered breathing in both short and intermediate term.

New drug candidates may offer effective treatment options for OSA patients.

A new sub-specialty, Cardiovascular-Endocrine-Metabolic Medicine, is proposed to unify care across multiple specialties.

Healthcare systems should consider integrating this new sub-specialty for improved patient outcomes.